Report Sections

See All Reports

Coronavirus Infections (840) Severe Acute Respiratory Syndrome (575) Infection (491) Pneumonia (381) Communicable Diseases (217) Respiratory Distress Syndrome, Adult (187) Acute Lung Injury (148) Respiratory Distress Syndrome, Newborn (148) (134) Syndrome (129) Virus Diseases (98) Depression (92) Pneumonia, Viral (81) Critical Illness (69) Anxiety Disorders (57) Neoplasms (47) Respiratory Tract Infections (46) Disease (41) Diabetes Mellitus (39) Cardiovascular Diseases (38) Stress Disorders, Post-Traumatic (38) Emergencies (36) Wounds and Injuries (36) Depressive Disorder (35) Inflammation (35) Lung Diseases (33) Stress Disorders, Traumatic (33) Stress, Psychological (33) Respiratory Tract Diseases (31) Hypoxia (30) Lung Injury (30) Acute Kidney Injury (29) Mental Disorders (29) Thrombosis (29) Influenza, Human (27) Hypertension (25) Respiration Disorders (23) Disease Progression (22) Fibrosis (22) Cognitive Dysfunction (21) Olfaction Disorders (21) Arthritis (20) Diabetes Mellitus, Type 2 (20) Sclerosis (20) Burnout, Psychological (19) Multiple Sclerosis (19) Pulmonary Disease, Chronic Obstructive (19) Respiratory Aspiration (19) Thromboembolism (19) Embolism (18) Lung Diseases, Obstructive (18) Pulmonary Fibrosis (18) HIV Infections (17) Kidney Diseases (17) Stroke (17) Blood Coagulation Disorders (16) Heart Failure (16) Hemostatic Disorders (16) Pulmonary Embolism (16) Arthritis, Rheumatoid (15) Asthma (15) Chronic Disease (15) Heart Diseases (15) Lung Diseases, Interstitial (15) Lung Neoplasms (15) Myocardial Infarction (15) Substance-Related Disorders (15) Autism Spectrum Disorder (14) Chronic Pain (14) Crohn Disease (14) Brain Injuries (13) Diabetes Mellitus, Type 1 (13) Infarction (13) Venous Thrombosis (12) Autistic Disorder (11) Carcinoma (11) Colitis (11) Colitis, Ulcerative (11) Dyspnea (11) Feeding and Eating Disorders (11) Obesity (11) Rheumatic Diseases (11) Ulcer (11) Alzheimer Disease (10) Burnout, Professional (10) Leukemia (10) Lymphoma (10) Myocarditis (10) Overweight (10) Parkinson Disease (10) Pregnancy Complications (10) Renal Insufficiency, Chronic (10) Respiratory Syncytial Virus Infections (10) Sepsis (10) Brain Injuries, Traumatic (9) Collagen Diseases (9) Coronary Artery Disease (9) Cystic Fibrosis (9) Dementia (9) Depression, Postpartum (9) Frailty (9) Inflammatory Bowel Diseases (9) Liver Diseases (9) Musculoskeletal Pain (9) Pneumonia, Ventilator-Associated (9) Pulmonary Valve Insufficiency (9) Renal Insufficiency (9) Venous Thromboembolism (9) Vitamin D Deficiency (9) Weight Loss (9) Alcohol Drinking (8) Alcoholism (8) Hematologic Neoplasms (8) Infertility (8) Ischemia (8) Parasomnias (8) Problem Behavior (8) Psychotic Disorders (8) RNA Virus Infections (8) Breast Neoplasms (7) Convalescence (7) Coronary Disease (7) Dyssomnias (7) Fatigue (7) Metabolic Syndrome (7) Migraine Disorders (7) Myocardial Ischemia (7) Neoplasm Metastasis (7) Psoriasis (7) Schizophrenia (7) Shock (7) Spinal Cord Injuries (7) Toxemia (7) Acute Coronary Syndrome (6) Brain Diseases (6) Bronchiectasis (6) Carcinoma, Non-Small-Cell Lung (6) Child Development Disorders, Pervasive (6) Colorectal Neoplasms (6) Deglutition Disorders (6) Delirium (6) Disease Susceptibility (6) Immune System Diseases (6) Immunologic Deficiency Syndromes (6) Kidney Failure, Chronic (6) Lupus Erythematosus, Systemic (6) Lymphopenia (6) Multiple Organ Failure (6) Neurologic Manifestations (6) Osteoarthritis (6) (6) Pediatric Obesity (6) Prostatic Neoplasms (6) Sleep Apnea Syndromes (6) Sleep Apnea, Obstructive (6) Appendicitis (5) Arthritis, Psoriatic (5) Autoimmune Diseases (5) Coronaviridae Infections (5) Cross Infection (5) Depressive Disorder, Major (5) Dermatitis (5) Disseminated Intravascular Coagulation (5) Fibromyalgia (5) Gastroparesis (5) Head and Neck Neoplasms (5) Hypersensitivity (5) Idiopathic Pulmonary Fibrosis (5) Leukemia, Lymphoid (5) Metabolic Diseases (5) Mobility Limitation (5) Nervous System Diseases (5) Occupational Stress (5) Osteoarthritis, Knee (5) Pancreatic Neoplasms (5) Premature Birth (5) Triple Negative Breast Neoplasms (5) Acquired Immunodeficiency Syndrome (4) Acute Disease (4) Adenoviridae Infections (4) Amyotrophic Lateral Sclerosis (4) Anemia, Sickle Cell (4) Arrhythmias, Cardiac (4) Asymptomatic Diseases (4) Atrial Fibrillation (4) Attention Deficit Disorder with Hyperactivity (4) Behavior, Addictive (4) Body Weight (4) Carcinoma, Renal Cell (4) Cognition Disorders (4) Coinfection (4) Colonic Neoplasms (4) Death (4) Dermatitis, Atopic (4) Digestive System Diseases (4) Eczema (4) Embolism and Thrombosis (4) Endometriosis (4) Gastrointestinal Diseases (4) Headache (4) Heart Arrest (4) Hematologic Diseases (4) Hemophilia A (4) Hemorrhage (4) Hypertension, Pulmonary (4) Intestinal Diseases (4) Liver Cirrhosis (4) Macular Degeneration (4) Malnutrition (4) Motor Neuron Disease (4) (4) Mycobacterium Infections (4) Panic Disorder (4) Peripheral Arterial Disease (4) Postoperative Complications (4) Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) Prediabetic State (4) Signs and Symptoms, Respiratory (4) Sjogren's Syndrome (4) Sleep Initiation and Maintenance Disorders (4) Spondylarthritis (4) Systemic Inflammatory Response Syndrome (4) Thrombophilia (4) Tobacco Use Disorder (4) Vascular Diseases (4) Ventricular Dysfunction (4) Ventricular Dysfunction, Left (4) Apnea (3) Bacteremia (3) Bacterial Infections (3) Bulimia (3) Cardiomyopathies (3) Celiac Disease (3) Cerebral Palsy (3) Chilblains (3) Common Cold (3) Congenital Abnormalities (3) Developmental Disabilities (3) Dysgeusia (3) Endocrine System Diseases (3) Eye Diseases (3) Fatigue Syndrome, Chronic (3) Fatty Liver (3) Fever (3) Fistula (3) Fractures, Bone (3) Ganglion Cysts (3) Giant Cell Arteritis (3) Glucose Intolerance (3) Glucose Metabolism Disorders (3) Heart Defects, Congenital (3) Hepatitis C (3) Huntington Disease (3) Hyperglycemia (3) Hypothermia (3) Kidney Calculi (3) Leukemia, Lymphocytic, Chronic, B-Cell (3) Leukemia, Myeloid, Acute (3) Macular Edema (3) Measles (3) Melanoma (3) Meningitis (3) Mouth Diseases (3) Mucocutaneous Lymph Node Syndrome (3) Multiple Myeloma (3) Multiple Sclerosis, Relapsing-Remitting (3) Myelodysplastic Syndromes (3) Myeloproliferative Disorders (3) Neoplasms, Plasma Cell (3) Neuroendocrine Tumors (3) Non-alcoholic Fatty Liver Disease (3) Obesity, Morbid (3) Obstetric Labor, Premature (3) Ovarian Neoplasms (3) Paramyxoviridae Infections (3) Peripheral Nervous System Diseases (3) Peripheral Vascular Diseases (3) Polymyalgia Rheumatica (3) Pregnancy Complications, Infectious (3) Psychological Trauma (3) Pulmonary Edema (3) Rare Diseases (3) Rheumatic Fever (3) ST Elevation Myocardial Infarction (3) Seizures (3) Shock, Septic (3) Sleep Wake Disorders (3) Small Cell Lung Carcinoma (3) Suicidal Ideation (3) Tachycardia (3) Taste Disorders (3) Tuberculosis (3) Ageusia (2) Agoraphobia (2) Alcoholic Intoxication (2) Alopecia (2) Alpha 1-Antitrypsin Deficiency (2) Angina Pectoris (2) Anxiety, Separation (2) Aortic Valve Stenosis (2) Arteritis (2) Asymptomatic Infections (2) Atherosclerosis (2) Atrophy (2) Back Pain (2) Behcet Syndrome (2) Binge-Eating Disorder (2) Bipolar Disorder (2) Bronchitis (2) Bronchitis, Chronic (2) Bronchopulmonary Dysplasia (2) Caliciviridae Infections (2) Carcinoma, Small Cell (2) Carcinoma, Squamous Cell (2) Cataract (2) Cholangitis (2) Clinical Deterioration (2) Clostridium Infections (2) Communicable Diseases, Emerging (2) Communication Disorders (2) Compassion Fatigue (2) Compulsive Personality Disorder (2) Conjunctivitis (2) Depressive Disorder, Treatment-Resistant (2) Diabetic Nephropathies (2) Diabetic Neuropathies (2) Diarrhea (2) Drug-Related Side Effects and Adverse Reactions (2) Emphysema (2) Endocarditis (2) Epilepsy (2) Facies (2) Fractures, Stress (2) Gastroenteritis (2) Gastroesophageal Reflux (2) Genetic Predisposition to Disease (2) Glioblastoma (2) Gout (2) Healthcare-Associated Pneumonia (2) Heart Failure, Systolic (2) Hepatitis (2) Hepatitis A (2) Humeral Fractures (2) Hyperkinesis (2) Hyperphagia (2) Hyperplasia (2) Hypertension, Pregnancy-Induced (2) Hypotension (2) Hypoventilation (2) Infertility, Male (2) Intervertebral Disc Degeneration (2) Ischemic Attack, Transient (2) Jaundice (2) Joint Diseases (2) Leukemia, Myeloid (2) Low Back Pain (2) Lymphedema (2) Lymphoma, B-Cell (2) Lymphoma, Mantle-Cell (2) Lymphoproliferative Disorders (2) Meningitis, Meningococcal (2) Mood Disorders (2) Mucositis (2) Muscle Spasticity (2) Muscular Dystrophies (2) Mutism (2) Mycoses (2) Myofascial Pain Syndromes (2) Myositis (2) Necrosis (2) Nephrolithiasis (2) Nerve Degeneration (2) Neurocognitive Disorders (2) Neurodevelopmental Disorders (2) Nidovirales Infections (2) Noncommunicable Diseases (2) Nutrition Disorders (2) Obsessive-Compulsive Disorder (2) Oral Manifestations (2) Oropharyngeal Neoplasms (2) Pain (2) Pain, Postoperative (2) Pancreatitis (2) Paresis (2) Periodontal Diseases (2) Phobia, Social (2) Phobic Disorders (2) Pneumonia, Bacterial (2) Pneumonia, Pneumocystis (2) Pre-Eclampsia (2) Preleukemia (2) Pulmonary Eosinophilia (2) Purpura, Thrombocytopenic, Idiopathic (2) Recurrence (2) Respiratory Sounds (2) Rupture (2) Sarcoidosis (2) Sarcopenia (2) (2) Scleroderma, Systemic (2) Spinal Diseases (2) Sprains and Strains (2) Squamous Cell Carcinoma of Head and Neck (2) Stillbirth (2) Stomatitis (2) Suicide (2) Temporomandibular Joint Disorders (2) Temporomandibular Joint Dysfunction Syndrome (2) Thoracic Diseases (2) Thrombocytopenia (2) Thyroid Diseases (2) Trauma and Stressor Related Disorders (2) Urinary Bladder, Overactive (2) Urinary Tract Infections (2) Uterine Cervical Neoplasms (2) Uveitis (2) Vision Disorders (2) Vision, Low (2) Wet Macular Degeneration (2) Yellow Fever (2) Abortion, Spontaneous (1) Abruptio Placentae (1) Acalculous Cholecystitis (1) (1) Adenocarcinoma (1) Adjustment Disorders (1) Adrenal Insufficiency (1) Aggression (1) Alcohol Drinking in College (1) Alcohol-Related Disorders (1) Altitude Sickness (1) Alveolitis, Extrinsic Allergic (1) Amblyopia (1) Anemia (1) Anemia, Aplastic (1) Anemia, Iron-Deficiency (1) Aneurysm (1) Aneurysm, Ruptured (1) Angina, Stable (1) Angioedema (1) Angioedemas, Hereditary (1) Ankle Fractures (1) Anorexia (1) Anorexia Nervosa (1) Arachnoiditis (1) Arthritis, Juvenile (1) Aspergillosis (1) Aspergillosis, Allergic Bronchopulmonary (1) Asphyxia Neonatorum (1) Asthenopia (1) Atrioventricular Block (1) Autonomic Nervous System Diseases (1) Barotrauma (1) Biliary Tract Neoplasms (1) Birth Weight (1) Blister (1) Body Weight Changes (1) Bone Diseases, Metabolic (1) Bone Marrow Diseases (1) Bradycardia (1) Brain Concussion (1) Brain Neoplasms (1) Breast Cancer Lymphedema (1) Bronchial Diseases (1) Bronchiolitis (1) Brucellosis (1) Bruxism (1) Bulimia Nervosa (1) (1) Calculi (1) Carcinoma in Situ (1) Carcinoma, Ductal (1) Carcinoma, Ductal, Breast (1) Carcinoma, Hepatocellular (1) Carcinoma, Intraductal, Noninfiltrating (1) Carcinoma, Ovarian Epithelial (1) Cardiotoxicity (1) Cardiovascular Abnormalities (1) Cellulitis (1) Cerebral Hemorrhage (1) Cerebrovascular Disorders (1) Chest Pain (1) Chlamydia Infections (1) Cholangiocarcinoma (1) Cholangitis, Sclerosing (1) Cholecystitis (1) Cholecystitis, Acute (1) Chorea (1) Chronic Traumatic Encephalopathy (1) Ciliary Motility Disorders (1) Colitis, Ulcerativ (1) Colonic Diseases (1) (1) Compulsive Behavior (1) Consciousness Disorders (1) Constipation (1) Constriction, Pathologic (1) Conversion Disorder (1) (1) Coronary Restenosis (1) Coronary Stenosis (1) (1) Coronavirus Infect (1) Cough (1) Coxsackievirus Infections (1) Crohn Dise (1) Cryopyrin-Associated Periodic Syndromes (1) Deafness (1) Death, Sudden, Cardiac (1) Dehydration (1) Dental Calculus (1) Dental Plaque (1) DiGeorge Syndrome (1) Diabetic Foot (1) Digestive System Neoplasms (1) Diphtheria (1) Down Syndrome (1) Drug Overdose (1) Dry Eye Syndromes (1) Dysentery, Bacillary (1) Dyskinesias (1) Dyspareunia (1) Dysphonia (1) Eclampsia (1) Emergence Delirium (1) Encephalitis (1) Endophthalmitis (1) Endotoxemia (1) Enterocolitis (1) Enterocolitis, Pseudomembranous (1) Enuresis (1) Eosinophilic Esophagitis (1) Epstein-Barr Virus Infections (1) Escherichia coli Infections (1) Esophageal Fistula (1) Esophageal and Gastric Varices (1) Esophagitis (1) Esophagitis, Peptic (1) Eye Infections (1) Fabry Disease (1) Facial Pain (1) Familial Mediterranean Fever (1) Femoral Fractures (1) Femoral Neck Fractures (1) Fetal Growth Retardation (1) Fetal Membranes, Premature Rupture (1) Fever of Unknown Origin (1) Food Hypersensitivity (1) Foot Ulcer (1) Fractures, Closed (1) Gait Disorders, Neurologic (1) Gambling (1) Gastrointestinal Stromal Tumors (1) Gaucher Disease (1) Genetic Diseases, Inborn (1) Geographic Atrophy (1) Gestational Weight Gain (1) Gingivitis, Necrotizing Ulcerative (1) Glomerulonephritis, IGA (1) Glomerulonephritis, Membranous (1) Guillain-Barre Syndrome (1) Halitosis (1) Headache Disorders, Secondary (1) Hearing Loss (1) Hearing Loss, Conductive (1) Heart Block (1) Heart Failure, Diastolic (1) Heart Murmurs (1) Helminthiasis (1) Hematoma (1) Hematoma, Subdural (1) Hematoma, Subdural, Chronic (1) Hemoglobinopathies (1) Hepatitis B (1) Hepatitis, Alcoholic (1) Hereditary Autoinflammatory Diseases (1) Herpes Labialis (1) Herpes Zoster (1) Hoarseness (1) Hodgkin Disease (1) Hot Flashes (1) Hyaline Membrane Disease (1) Hyperaldosteronism (1) Hypercapnia (1) Hyperkalemia (1) Hyperphosphatemia (1) Hypersensitivity, Immediate (1) Hypertrophy (1) Hypokalemia (1) Hyponatremia (1) Hypoparathyroidism (1) Iatrogenic Disease (1) (1) Infant, Newborn, Diseases (1) (1) Infec (1) Infecti (1) Infectious Mononucleosis (1) Infertility, Female (1) Intellectual Disability (1) Intermittent Claudication (1) Intestinal Atresia (1) Intracranial Aneurysm (1) Intracranial Hypertension (1) Intracranial Thrombosis (1) Jaundice, Obstructive (1) Keratoconjunctivitis (1) Keratoconjunctivitis Sicca (1) Keratosis (1) Keratosis, Actinic (1) Language Disorders (1) Leishmaniasis (1) Leukemia, Myelomonocytic, Acute (1) Leukemia, Myelomonocytic, Chronic (1) Leukemia, Prolymphocytic (1) Leukemia, Prolymphocytic, T-Cell (1) Lichen Sclerosus et Atrophicus (1) Liver Cirrhosis, Biliary (1) Liver Failure (1) Lung Ne (1) Lyme Disease (1) Lymphocytosis (1) Lymphoma, Large B-Cell, Diffuse (1) Lymphoma, Non-Hodgkin (1) Macrophage Activation Syndrome (1) Malaria (1) Maternal Death (1) Maxillofacial Injuries (1) May-Thurner Syndrome (1) Memory Disorders (1) Meningococcal Infections (1) Meningomyelocele (1) Menorrhagia (1) Menstruation Disturbances (1) Metabolism, Inborn Errors (1) Microvascular Rarefaction (1) Mitochondrial Diseases (1) Molluscum Contagiosum (1) Monoclonal Gammopathy of Undetermined Significance (1) Mouth, Edentulous (1) Movement Disorders (1) Multiple Chronic Conditions (1) Muscular Atrophy (1) Muscular Dystrophy, Duchenne (1) Myalgia (1) Myelodysplastic-Myeloproliferative Diseases (1) Myocardial Reperfusion Injury (1) Nasal Polyps (1) Needlestick Injuries (1) Neonatal Sepsis (1) Neoplasms, Germ Cell and Embryonal (1) Neoplastic Cells, Circulating (1) Nephritis (1) Nervous System Malformations (1) Neurobehavioral Manifestations (1) Neuromuscular Diseases (1) Neuromyelitis Optica (1) Obsessive Behavior (1) Olfactory Nerve Injuries (1) Oligospermia (1) Opioid-Related Disorders (1) Orbital Cellulitis (1) Osteoarthritis, Hip (1) Osteochondritis (1) Osteomyelitis (1) Otitis (1) Otitis Media (1) Otitis Media with Effusion (1) Overwei (1) Pain, Intractable (1) Pain, Procedural (1) Papillomavirus Infections (1) Paraproteinemias (1) Parkin (1) Peanut Hypersensitivity (1) Perinatal Death (1) Periodontal Pocket (1) Peritoneal Neoplasms (1) Pharyngeal Diseases (1) Pneumon (1) Polyps (1) Pregnancy in Diabetics (1) Presbyopia (1) Primary Dysautonomias (1) Primary Myelofibrosis (1) Prostatic Hyperplasia (1) Protein Deficiency (1) Protein-Energy Malnutrition (1) Pseudomonas Infections (1) Psychophysiologic Disorders (1) Puerperal Infection (1) Pulmonary Alveolar Proteinosis (1) Pulmonary Aspergillosis (1) Pulmonary Atelectasis (1) Pulmonary Heart Disease (1) Rabies (1) Radiculopathy (1) Rectal Fistula (1) Rectal Neoplasms (1) Reperfusion Injury (1) Resp (1) Respiratory Distre (1) Respiratory Distress Sy (1) Respiratory Hypersensitivity (1) Restless Legs Syndrome (1) Retinal Vein Occlusion (1) Rhinitis (1) Rhinitis, Allergic (1) Rhinitis, Allergic, Seasonal (1) Sarcoma (1) Schizophrenia Spectrum and Other Psychotic Disorders (1) Scleroderma, Localized (1) (1) Self-Injurious Behavior (1) Sexually Transmitted Diseases (1) Sexually Transmitted Diseases, Bacterial (1) Shock, Cardiogenic (1) Short Bowel Syndrome (1) Shoulder Fractures (1) Signs and Symptoms, Digestive (1) Skin Abnormalities (1) Skin Diseases (1) Skin Manifestations (1) Skin Neoplasms (1) Skull Fractures (1) Sleep Apnea, Central (1) Soft Tissue Neoplasms (1) Somatoform Disorders (1) Speech Sound Disorder (1) Spina Bifida Cystica (1) Spinal Cord Diseases (1) Spinal Dysraphism (1) Spinal Stenosis (1) Spondylitis (1) Spondylitis, Ankylosing (1) Spondylolisthesis (1) Status Epilepticus (1) Stress Disorders, Traumatic, Acute (1) Subarachnoid Hemorrhage (1) Superinfection (1) Syncope (1) Syncope, Vasovagal (1) Synovial Cyst (1) Tachycardia, Sinus (1) Tachycardia, Supraventricular (1) Tachycardia, Ventricular (1) Tachypnea (1) Thalassemia (1) Thrombophlebitis (1) Thrombotic Microangiopathies (1) Tissue Adhesions (1) Tonsillitis (1) Torsades de Pointes (1) Tourette Syndrome (1) Trauma, Nervous System (1) Trichuriasis (1) Tuberculosis, Meningeal (1) Tuberculosis, Pulmonary (1) Urinary Bladder Neoplasms (1) Urinary Bladder, Underactive (1) Urinary Incontinence (1) Urinary Retention (1) Urogenital Neoplasms (1) Urologic Diseases (1) Urticaria (1) Uterine Neoplasms (1) Vaginal Neoplasms (1) Venous Insufficiency (1) Ventricular Dysfunction, Right (1) Virus (1) Vitamin D Deficie (1) Voice Disorders (1) Von Willebrand Diseases (1) Vulvar Lichen Sclerosus (1) Vulvar Neoplasms (1) Waldenstrom Macroglobulinemia (1) Weight Gain (1) Xerostomia (1) beta-Thalassemia (1)

D003680: Deglutition Disorders

Developed by Shray Alag, The Harker School
Sections: Correlations, Clinical Trials, and HPO

Correlations computed by analyzing all clinical trials.

Navigate: Clinical Trials and HPO


Correlated Drug Terms (18)


Name (Synonyms) Correlation
drug1662 Fiberoptic Endoscopic Evaluation of Swallowing Wiki 0.58
drug4953 feces samples (COVI-BIOME ancillary study) Wiki 0.41
drug4860 blood sample for seroepidemiological investigation Wiki 0.41
Name (Synonyms) Correlation
drug5252 sweat samples (COVIDOG ancillary study) Wiki 0.41
drug2982 Optimal-Massive Intervention Wiki 0.41
drug1118 Control (standard clinical practice) Wiki 0.41
drug1663 Fibreoptic Endoscopic Evaluation of Swallowing (FEES) Wiki 0.41
drug1398 Dysphagia Handicap Index (DHI) Wiki 0.41
drug4223 Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST) Wiki 0.41
drug4093 Standard care delivered in the isolation hospitals. Wiki 0.41
drug4465 Tramadol Wiki 0.41
drug4662 Videofluoroscopy Wiki 0.41
drug4704 Voice Symptom Scale (VoiSS) Wiki 0.41
drug4861 blood samples Wiki 0.29
drug4859 blood sample Wiki 0.26
drug4212 Survey Wiki 0.10
drug1150 Convalescent plasma Wiki 0.09
drug3195 Placebo Wiki 0.02

Correlated MeSH Terms (13)


Name (Synonyms) Correlation
D006685 Hoarseness NIH 0.41
D003681 Dehydration NIH 0.41
D055154 Dysphonia NIH 0.41
Name (Synonyms) Correlation
D014832 Voice Disorders NIH 0.41
D013896 Thoracic Diseases NIH 0.29
D009059 Mouth Diseases NIH 0.24
D044342 Malnutrition NIH 0.20
D002318 Cardiovascular Diseases NIH 0.07
D004194 Disease NIH 0.06
D012141 Respiratory Tract Infections NIH 0.06
D007239 Infection NIH 0.02
D045169 Severe Acute Respiratory Syndrome NIH 0.02
D018352 Coronavirus Infections NIH 0.01

Correlated HPO Terms (8)


Name (Synonyms) Correlation
HP:0002015 Dysphagia HPO 1.00
HP:0001609 Hoarse voice HPO 0.41
HP:0001618 Dysphonia HPO 0.41
Name (Synonyms) Correlation
HP:0001621 Weak voice HPO 0.41
HP:0001944 Dehydration HPO 0.41
HP:0004395 Malnutrition HPO 0.20
HP:0001626 Abnormality of the cardiovascular system HPO 0.07
HP:0011947 Respiratory tract infection HPO 0.06

Clinical Trials

Navigate: Correlations   HPO

There are 6 clinical trials


1 Oropharyngeal Dysphagia and Malnutrition in Patients Infected by SARS-CoV-2: Prevalence and Needs of Compensatory Treatment and Follow up in Patients Admitted by COVID-19 at the Consorci Sanitari Del Maresme

Background: Oropharyngeal dysphagia (OD) is a common complication in/post ICU patients that have been with intubation/mechanical ventilation or with tracheotomies or NG tubes, in patients with acute respiratory infection/pneumonia/respiratory insufficiency with a severe disease needing high concentration of oxygen or noninvasive mechanical ventilation and also in patients discharged from acute hospitals to rehabilitation centers, nursing homes or other facilities. All these situations are common for COVID-19 patients that are currently filling our hospitals due to the pandemic expansion of SARS-CoV-2. OD is associated to prolonged hospitalization, dehydration and severe nutritional and respiratory complications -aspiration pneumonia-, hospital readmissions and mortality. Aim: to assess the prevalence of OD and nutritional risk in these patients and to know their needs of compensatory treatment following the application of an early intervention, and to assess whether OD and malnutrition are indicators of poor prognosis for COVID-19 patients. Methods: prospective study in which we will use the volume-viscosity swallowing test (V-VST) to assess the prevalence of OD, and NRS2002 to assess the nutritional risk in admitted patients with confirmed COVID-19 at the Consorci Sanitari del Maresme, Catalonia, Spain. We will register also results of the EAT-10, nutritional status, the needs of compensatory treatments of these patients following an early intervention with fluid and nutritional adaptation and use of nutritional supplements. We will also collect other clinical variables from medical history of the patient related to hospitalization and we will follow the clinical complications and nutritional status at 3 and 6 months follow up.

NCT04346212
Conditions
  1. Oropharyngeal Dysphagia
  2. COVID-19
  3. Sars-CoV2
  4. Nutrition
Interventions
  1. Diagnostic Test: Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST)
MeSH:Deglutition Disorders
HPO:Dysphagia Oral-pharyngeal dysphagia

Primary Outcomes

Description: Changes in the prevalence of oropharyngeal dysphagia according to a clinical assessment tool, the Volume-Viscosity Swallowing Test (V-VST).

Measure: Changes in the prevalence of oropharyngeal dysphagia

Time: From April to December 2020. And at 3 and 6 months follow-up.

Secondary Outcomes

Description: Changes in the eating assessment tool (EAT-10 score). A tool that goes from 0 to 40 points and indicates that the patient is at risk of oropharyngeal dysphagia if he/she presents 3 or more points

Measure: Changes in the swallowing screening

Time: From April to December 2020. And at 3 and 6 months follow-up.

Description: Changes in the percentage of patients with impairements in efficacy and/or safety of swallow.

Measure: Changes in the swallowing status

Time: From April to December 2020. And at 3 and 6 months follow-up.

Description: Changes in the nutritional status of study patients (% malnourished, at risk of malnutrition or wellnourished).

Measure: Changes in the nutritonal status of study patient's.

Time: From April to December 2020. And at 3 and 6 months follow-up.

Description: Changes in the fluid (volume and viscosity) requirements of study patients.

Measure: Changes in the needs of compensatory treatments in those patients with oropharyngeal dysphagia (fluid adaptation).

Time: From April to December 2020. And at 3 and 6 months follow-up.

Description: Changes in the nutritional adaptation requirements (type of diet and need of nutritional supplementation).

Measure: Changes in the needs of compensatory treatments in those patients with oropharyngeal dysphagia (nutritional adaptation).

Time: From April to December 2020. And at 3 and 6 months follow-up.

Description: Changes in the incidence of hospital readmissions: number of hospital readmissions/patient/6 months.

Measure: Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (incidence of readmissions).

Time: 3 and 6 months from inclusion.

Description: Changes in the prevalence: % of patients with hospital readmissions during the follow-up.

Measure: Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (prevalence of readmissions).

Time: 3 and 6 months from inclusion.

Description: Incidence: number of visits to the emergency department/patient/ 3 or 6 months.

Measure: Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (number of visits to emergency department).

Time: 3 and 6 months from inclusion.

Description: Prevalence: % of patients visiting the emergency department during the follow-up.

Measure: Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (percentage of visits to emergency department).

Time: 3 and 6 months from inclusion.

Description: Incidence of respiratory infections (including pneumonia, and COPD exacerbations).

Measure: Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (respiratory complications).

Time: 3 and 6 months from inclusion.

Description: 3 and 6 months mortality.

Measure: Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (mortality).

Time: 3 and 6 months from inclusion.
2 Dysphagia in Thoracic Surgical Patients: Incidence, Risk-factors, and Health Related Outcomes

The proposed study seeks to determine the incidence of dysphagia and vocal fold mobility impairment (VFMI) in individuals undergoing throacic surgical procedures. It also seeks to determine the impact of postoperative swallowing impairment on health-related outcomes.

NCT04487028
Conditions
  1. Thoracic Diseases
Interventions
  1. Procedure: Fiberoptic Endoscopic Evaluation of Swallowing
MeSH:Deglutition Disorders Thoracic Diseases
HPO:Dysphagia Oral-pharyngeal dysphagia

Primary Outcomes

Description: This scale is a validated measure used by trained blinded clinicians to assign ratings of safety to swallowing bolus trials. The development and use of an 8-point, equal-appearing interval scale (8 being best; 1 being worst) to describe penetration and aspiration events are described. Scores are determined primarily by the depth to which material passes in the airway and by whether or not material entering the airway is expelled.

Measure: Penetration Aspiration Scale

Time: Baseline

Secondary Outcomes

Description: This scale is a validated measure used by trained blinded clinicians to assign ratings of efficiency to swallowing bolus trials. The Yale Pharyngeal Residue Severity Rating Scale was developed, standardized, and validated to provide reliable, anatomically defined, and image-based assessment of post-swallow pharyngeal residue severity as observed during fiberoptic endoscopic evaluation of swallowing (FEES). It is a five-point ordinal rating scale based on residue location (vallecula and pyriform sinus) and amount (none, trace, mild, moderate, and severe).

Measure: Yale Residue Severity Rating Scale

Time: Baseline

Other Outcomes

Description: During a Fiberoptic Endoscopic Evaluation of Swallowing (FEES), the vocal folds will be visualized using a small camera passed through the open nasal passage. The patient will be asked to make a series of vocal tasks so that we can visualize their movement, any immobility will be notated.

Measure: Vocal Fold Mobility Impairment

Time: Baseline
3 Development of a Dysphagia Risk Stratification Tool and Clinical Bedside Screening Tool in Cardiovascular Surgical Patients

The proposed study seeks to determine the incidence of dysphagia and vocal fold mobility impairment (VFMI) in individuals undergoing cardiovascular surgical procedures. It also seeks to determine the impact of postoperative swallowing impairment on health-related outcomes.

NCT04496986
Conditions
  1. Cardiovascular Diseases
Interventions
  1. Procedure: Fiberoptic Endoscopic Evaluation of Swallowing
MeSH:Deglutition Disorders Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system Dysphagia Oral-pharyngeal dysphagia

Primary Outcomes

Description: This scale is a validated measure used by trained blinded clinicians to assign ratings of safety to swallowing bolus trials. The development and use of an 8-point, equal-appearing interval scale (8 being best; 1 being worst) to describe penetration and aspiration events are described. Scores are determined primarily by the depth to which material passes in the airway and by whether or not material entering the airway is expelled.

Measure: Penetration Aspiration Scale

Time: Baseline (Prior to surgery)

Description: This scale is a validated measure used by trained blinded clinicians to assign ratings of safety to swallowing bolus trials. The development and use of an 8-point, equal-appearing interval scale (8 being best; 1 being worst) to describe penetration and aspiration events are described. Scores are determined primarily by the depth to which material passes in the airway and by whether or not material entering the airway is expelled.

Measure: Penetration Aspiration Scale

Time: Follow-up - Within 72 hours following extubation from surgery

Secondary Outcomes

Description: This scale is a validated measure used by trained blinded clinicians to assign ratings of efficiency to swallowing bolus trials. The Yale Pharyngeal Residue Severity Rating Scale was developed, standardized, and validated to provide reliable, anatomically defined, and image-based assessment of post-swallow pharyngeal residue severity as observed during fiberoptic endoscopic evaluation of swallowing (FEES). It is a five-point ordinal rating scale based on residue location (vallecula and pyriform sinus) and amount (none, trace, mild, moderate, and severe).

Measure: Yale Residue Severity Rating Scale

Time: Baseline (Prior to surgery)

Description: This scale is a validated measure used by trained blinded clinicians to assign ratings of efficiency to swallowing bolus trials. The Yale Pharyngeal Residue Severity Rating Scale was developed, standardized, and validated to provide reliable, anatomically defined, and image-based assessment of post-swallow pharyngeal residue severity as observed during fiberoptic endoscopic evaluation of swallowing (FEES). It is a five-point ordinal rating scale based on residue location (vallecula and pyriform sinus) and amount (none, trace, mild, moderate, and severe).

Measure: Yale Residue Severity Rating Scale

Time: Follow-up - Within 72 hours following extubation from surgery

Other Outcomes

Description: During a Fiberoptic Endoscopic Evaluation of Swallowing (FEES), the vocal folds will be visualized using a small camera passed through the open nasal passage. The patient will be asked to make a series of vocal tasks so that we can visualize their movement, any immobility will be notated.

Measure: Vocal Fold Mobility Impairment

Time: Baseline (Prior to surgery)

Description: During a Fiberoptic Endoscopic Evaluation of Swallowing (FEES), the vocal folds will be visualized using a small camera passed through the open nasal passage. The patient will be asked to make a series of vocal tasks so that we can visualize their movement, any immobility will be notated.

Measure: Vocal Fold Mobility Impairment

Time: Follow-up - Within 72 hours following extubation from surgery
4 Experiences in Dysphagia Management During COVID-19 Pandemic

The current study is aimed to determine the procedures applied in the dysphagia clinics during the COVID-19 pandemic period. A questionnaire consisting of 30 questions will be implemented. Each participant will be asked to answer the questions.

NCT04509752
Conditions
  1. Dysphagia
  2. Covid19
Interventions
  1. Other: Survey
MeSH:Deglutition Disorders
HPO:Dysphagia Oral-pharyngeal dysphagia

Primary Outcomes

Description: An online survey will be designed to understand the current clinical conditions and current practice regarding dysphagia management during the pandemic period/normalization period

Measure: Online survey

Time: 3 months
5 Evaluation of the Effectiveness of an Optimal-Massive Intervention in Older Patients With Oropharyngeal Dysphagia

The aim of this study is to evaluate the efficacy of an optimal-massive intervention (OMI) based on increasing shear viscosity of fluids, nutritional support with oral nutritional supplements (ONS) and triple adaptation of food (rheological and textural, caloric and protein and organoleptic) and oral hygiene improvement on the incidence of respiratory infections in older patients with OD. We have designed a randomized clinical trial, with two parallel arms and 6 months follow-up. The study population will be constituted by older patients of 70 years or more with OD hospitalized at Hospital de Mataró by an acute process that will be identified by using the volume-viscosity swallow clinical test. We will consecutively recruit 500 subjects during admission (Geriatrics, Internal medicine, etc.) at the Hospital de Mataró. Patients included will be randomly assigned to one of both interventional groups: a) study intervention: multifactorial intervention based on fluid viscosity adaptation (with a xanthan gum thickener -> Nutilis Clear®), nutritional support with a triple adaptation of food (texture, caloric and protein content, organoleptic) + pre-thickened ONS and evaluation and treatment of oral hygiene (tooth brushing + antiseptic mouthwashes + professional dental cleaning), or b) control intervention: standard clinical practice (fluid adaptation with Nutilis Powder and simple texture adaptation for solids). Main outcome measures: respiratory infection incidence during the 6-month period follow-up. Secondary outcomes: mortality at 6 months, general hospital readmissions and readmissions due to respiratory infections, nutritional status, hydration status, quality of life, functional status, oral hygiene and dysphagia severity and its relationship with other study variables.

NCT04581486
Conditions
  1. Swallowing Disorder
  2. Oropharyngeal Dysphagia
  3. Respiratory Infection
  4. Malnutrition
  5. Dehydration
  6. Oral Disease
Interventions
  1. Other: Optimal-Massive Intervention
  2. Other: Control (standard clinical practice)
MeSH:Respiratory Tract Infections Deglutition Disorders Mouth Diseases Malnutrition Dehydration
HPO:Dehydration Dysphagia Malnutrition Oral-pharyngeal dysphagia Respiratory tract infection

Primary Outcomes

Description: Respiratory infections incidence (includes LRTI, pneumonia and exacerbations of COPD): all new episodes of respiratory infections recorded in the clinical history or in the reports presented by the patient will be recorded. LRTI: presence of at least 2 of the following symptoms without other cause to explain them: fever, cough, purulent expectoration, rhonchi or wheezing. Pneumonia: performing 1 or more radiographic tests with new condensation, fever or leukopenia or leukocytosis and at least: cough, purulent expectoration, dyspnea, tachypnea, suggestive auscultation or worsening of gas exchange. COPD exacerbation: acute exacerbation of COPD is a sudden worsening of COPD symptoms (shortness of breath, quantity and color of phlegm) that typically lasts for several days. It may be triggered by an infection with bacteria or viruses or by environmental pollutants.

Measure: Respiratory infections incidence.

Time: From discharge to 6 months follow-up

Secondary Outcomes

Description: Mortality: the date and reason for death will be recorded (hospitalization, 1, 3 and 6 months).

Measure: Mortality

Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.

Description: General readmissions and readmissions for respiratory infections (1, 3 and 6 months): LRTI, pneumonia and exacerbations of COPD: the reason for admission will be that stated in the hospital database (CMBDAH) according to CIM-10. The information source of the readmissions will be the registration of hospital discharges that is integrated into the hospital information system and that includes the CIM-10 codes of the main and secondary diagnoses of the episode that caused the admission, the date of admission and discharge and the days of hospitalization. Readmissions from pneumonia (codes CIM-10): J13, J18.1, J15.1, J14, J15.4, J15.211, J15.5, A48.1, J15.8, J18.0, J18.8, J69.0; readmissions for LRTI (no pneumonic): J20.0 - J20.9, J10.1, J11.1, J41.8, J44.1 and J44.0. Readmissions from exacerbation of COPD: J441.

Measure: General readmissions and readmissions for respiratory infections

Time: Through study completion, at 1, 3 and 6 months from disharge.

Description: Mini-nutritional assessment form (MNA) (hospitalization, 1, 3 and 6 months).

Measure: Nutritional status (MNA)

Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.

Description: Heigh in cm (hospitalization, 1, 3 and 6 months).

Measure: Nutritional status (Anthropometric measures)

Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.

Description: Weight in kg (hospitalization, 1, 3 and 6 months).

Measure: Nutritional status (Anthropometric measures2)

Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.

Description: Biochemical parameters from blood analysis (hospitalization, 3 and 6 months).

Measure: Nutritional status (Biochemical parameters)

Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.

Description: Hydration status: we will register total body water and intracellular water with bioimpedance (hospitalization, 1, 3 and 6 months).

Measure: Hydration status (bioimpedance)

Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.

Description: Quality of life: EQ-5D questionnaire will be used (hospitalization, 1, 3 and 6 months).

Measure: Quality of life of patients during the study period

Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.

Description: Functional status: we will use the Barthel Index (hospitalization, 1, 3 and 6 months).

Measure: Functional status

Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.

Description: Oral Hygiene: the OHI-S (simplified oroal hygiene index) will be collected (hospitalization, 1, 3 and 6 months).

Measure: Oral Hygiene

Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.

Description: Severity of dysphagia: according to the different viscosities that patients will be able to swallow and with the Functional Oral Intake Scale (V-VST/FOIS) (hospitalization, 1, 3 and 6 months).

Measure: Dysphagia severity

Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.

Other Outcomes

Description: Sociodemographic characteristics of the study population.

Measure: Sociodemographics

Time: Baseline

Description: Swallowing function (V-VST) (hospitalization, 1, 3 and 6 months).

Measure: Swallowing function (V-VST)

Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.

Description: Rate of institutionalization (1, 3 and 6 months).

Measure: Institutionalization

Time: Through study completion, at 1, 3 and 6 months from disharge.

Description: Drugs taken by the patient.

Measure: Pharmacological treatment

Time: Baseline

Description: Geriatric syndromes

Measure: Geriatric syndromes

Time: Baseline

Description: Fried criteria (hospitalization, 1, 3 and 6 months).

Measure: Frailty 1

Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.

Description: Edmonton frail scale (hospitalization, 1, 3 and 6 months).

Measure: Frailty 2

Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.

Description: Smoking and alcohol consumption

Measure: Toxic habits

Time: Baseline

Description: Compliance with the recommendations of the study intervention (adaptations of fluid, prescribed diets and oral hygiene) (hospitalization, 1, 3 and 6 months).

Measure: Compliance

Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.

Description: Palatability of the intervention products will be measured with the 5-point facial hedonic scale (hospitalization, 1, 3 and 6 months).

Measure: Palatability

Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.

Description: Acceptability of the dietes will be measured with the Food Action Rating Scale (hospitalization, 1, 3 and 6 months)

Measure: Acceptability

Time: Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.
6 Dysphagia and Dysphonia Outcomes in SARS CoV-2 (COVID-19): A Prospective Observational Cohort Study.

This study examines the presence, severity and natural history of dysphagia and dysphonia in the post-extubation and severely unwell COVID-19 patient.

NCT04584658
Conditions
  1. Dysphagia
  2. Dysphonia
  3. Subglottic Stenosis
  4. Voice Disorders
  5. Swallowing Disorder
  6. Covid19
  7. SARS (Severe Acute Respiratory Syndrome)
  8. SARS Pneumonia
  9. Quality of Life
  10. SARS-CoV-2 Infection
Interventions
  1. Diagnostic Test: Fibreoptic Endoscopic Evaluation of Swallowing (FEES)
  2. Diagnostic Test: Videofluoroscopy
  3. Other: Dysphagia Handicap Index (DHI)
  4. Other: Voice Symptom Scale (VoiSS)
MeSH:Infection Severe Acute Respiratory Syndrome Coronavirus Infections Deglutition Disorders Dysphonia Hoarseness Voice Disorders Disease
HPO:Dysphagia Dysphonia Hoarse voice Oral-pharyngeal dysphagia Weak voice

Primary Outcomes

Description: Based on therapy outcome measures from FEES, VoiS

Measure: Primary endpoint is severity of dysphonia and dysphagia at the time of initial assessment t = day 0 (for ITU patients: Day 0 = 24 hours after extubation or decannulation).

Time: t = day 0 (for ITU patients: Day 0 = 24 hours after extubation or decannulation).

Secondary Outcomes

Description: Clinical assessment including outcome measures, FEES and/or Videofluoroscopy

Measure: The severity of dysphonia and/or dysphagia over an initial 12 month period (at t = 14 days, 1 month, 3 months, 6 months, 9 months, 12 months)

Time: t = 14 days, 1 month, 3 months, 6 months, 9 months, 12 months

Description: Clinical assessment including outcome measures, FEES and/or Videofluoroscopy

Measure: The severity of dysphonia and/or dysphagia at t = day 5, day 10, day 14, day 21 - For in-patients only.

Time: t = day 5, day 10, day 14, day 21 - For in-patients only.

Description: Clinical assessment including outcome measures, FEES and/or Videofluoroscopy

Measure: Relationship between severity of dysphonia and/or dysphagia with grade of ARDS

Time: t = day 0 and 9 months

Description: Clinical assessment including outcome measures, FEES and/or Videofluoroscopy

Measure: Relationship between severity of dysphonia and/or dysphagia with length of intubation

Time: t = day 0 and 9 months

Description: Clinical assessment including outcome measures, FEES and/or Videofluoroscopy

Measure: Relationship between severity of dysphonia and/or dysphagia with duration of mechanical ventilation

Time: t = day 0 and 9 months

Description: Questionnaire assessment: This is a 30-item validated quality of life tool that is also a self-reporting tool. It appraises the impact of the patient's abnormal voice from an emotional perspective, related physical symptoms and stratifies the impairment itself in context of day to day activities. VoiSS is currently the most psychometrically robust voice outcome measure. Each item is scored 0 - 4 on the frequency responses: never, occasionally, some of the time, most of the time, always. The total score of 120 measures general voice pathology which is made up of Impairment = maximum score of 60; Emotional = maximum score of 32; Physical = maximum score of 28

Measure: Relationship between severity of dysphonia on quality of life using Voice Symptom Scale (VoiSS) questionnaire over time at day 0, 1 month and 9 months.

Time: t = day 0, 1 month and 9 months.

Description: Questionnaire assessment: This is a 25-item questionnaire assessing three domains: physical (9 items), functional (9 items), and emotional aspects (7 items) of the Quality of Life (QOL) in patients suffering with dysphagia. For each statement the patient checks if it applies to him/her all the time, some of the time or never. The suggested scores are 0, 2 and 4, respectively. Using this scoring system amounts to a DHI score range of 0 - 100. The higher the score, the worse the dysphagia related QOL. The patient is also asked to provide a rating of their own impression of the severity of the dysphagia experienced on a scale from 1 (normal) to 7 (severe problem).

Measure: Relationship between severity of dysphagia on quality of life using Dysphagia Handicap Index (DHI) questionnaire over time at day 0, 1 month and 9 months

Time: t = day 0, 1 month and 9 months

HPO Nodes


HP:0002015: Dysphagia
Genes 639
TGIF1 ASCC1 PIGN NOS1 TRNK TIMM8A CLTC COL7A1 NODAL CACNA1G VPS35 KCNK9 CAVIN1 KAT6B PRPS1 NEB POLR3B COL7A1 SDHD SHH TUBB4A KIT PRKRA NTRK1 NGLY1 RLIM RRM2B NUTM2B-AS1 OPTN IKZF1 SPECC1L ND1 NR4A2 CAV1 CHRNE YY1 SLC5A7 MYORG STUB1 ATXN10 DNAJB6 REPS1 ATP1A3 NDUFAF2 ATXN3 DDHD2 DAB1 NEB MEGF10 NODAL ATXN8OS GUCY1A1 ACTA1 ARHGAP29 EPB41L1 DCX VARS1 PLEC FGF8 GAS1 KCNQ5 GBA NDUFA6 FOXH1 IRF6 SCN4A MSX1 ANKRD11 CHRND NEB MRPS25 LAMB2 KLHL41 TBK1 CCR6 BRSK2 CYP27A1 PNKD IRF5 QDPR TPM2 ADNP DLL1 SIX3 MYO9A TIMM8A POLG NUP62 GCH1 SATB2 DCTN1 PSEN1 GMPPA GNS FOXH1 GRIN2B ND4 ADD3 PTS CDON TAF1 CUX1 COLQ SON KLHL41 ADAR ACOX1 UBQLN2 PANK2 GAS1 CRLF1 MAPT TK2 MYOT AR NEB KMT2A SPG11 MYH8 SPECC1L TPM2 CCR6 SCN3A KDM5B ZC4H2 CDON RELN ACTA1 CHRND IRF2BPL SLC5A7 RARS1 SHH DISP1 SCN4A TRNV PUS3 KIT ZIC2 PYGM PFN1 SLC52A3 MATR3 GALC ZMYND11 DISP1 CHRNE MAP2K2 SLC25A4 KIT SHH DNAJB6 NCAPG2 FOXH1 EEF1A2 HPDL KCNC3 CDH15 LIFR TDGF1 ALS2 ADH1C VPS13A CACNG2 NGLY1 GLI2 FGF8 ATXN1 GAS1 KLHL40 ATXN8 SCN4A ECM1 ATXN2 SCO2 FGFR1 CAV1 SDHC FTL NECTIN1 ND5 KIF1A MATR3 IDH2 PUF60 PDP1 ATXN3 DNM1L UBE3A TAF1 AFG3L2 TAOK1 FBXO7 STXBP1 TDGF1 ATXN7 SLC52A2 PPP3CA ALS2 KCND3 DYNC1H1 ZIC2 UBB CAMK2A POLG DISP1 PANK2 ZEB2 STAG2 LMX1B QDPR SIX3 GJB1 SIX3 MRPS28 SLC2A3 PDGFRA PLP1 TPM3 ATXN8 EPRS1 GRIN2D FLAD1 MFF ZIC2 ASPA VAMP1 SLC44A1 NOTCH3 ADCY6 SLC25A22 ND3 POLR3A LAMA2 C9ORF72 REEP1 SACS NECTIN1 HMBS POLR3B TRPM3 FBXL4 FGF8 CYP7B1 NPC1 MED17 SHH GRM1 SYT14 CAMK2B CACNA1A DLG1 SIK1 NDUFS1 LBR CACNA1A NOP56 TBCD NODAL ATXN1 ZFYVE26 KIF5A ERLIN2 PTCH1 HTT ZIC2 SDHA SLC9A6 NPC2 PCNA SCN4A CDC73 HTT DLL1 SETX PEX16 TRAPPC12 TUBB4A SQSTM1 CIC ATP7A RNASEH1 MMP1 DEAF1 REEP1 PLAA PLA2G6 CDON CHCHD10 SLC6A9 TBC1D23 PDE8B PTCH1 TYMP POLR3A CCN2 HLA-DRB1 SNCA PTCH1 ARX TPM3 MGME1 SPG7 HLA-DQA1 C19ORF12 DGUOK STUB1 UBE3A FGF8 GLI2 SLC1A4 GLI2 AGRN BRAF SNCA CNTNAP1 POLG2 POLG ACTB VAPB APP SET SLC18A3 DLX4 SDHB TRNL1 PANK2 SPG21 FGFR1 MYH7 MYOT CHMP2B C12ORF65 RAI1 FERMT1 EXOSC9 MYMK FLCN DNAJC13 COQ2 CRYAB DKK1 LINGO1 DDHD2 LMNB1 SQSTM1 KLHL40 RHBDF2 VAMP1 CACNA1G PIK3R5 FA2H NONO ALDH18A1 MAPT WFS1 PIGA ND2 AFG3L2 DGUOK MID1 PSAP SIGMAR1 GBA2 TGM6 SCARB2 ASH1L HPRT1 TARDBP CNTNAP2 VAC14 KIAA0319L MAPT YARS2 NDUFB8 GBA MBD5 COL7A1 VAMP1 NRXN1 SLC19A3 PTS SDHC GEMIN4 COQ4 VPS13A CSNK2B RRM2B ATP13A2 PANK2 ATXN2 REV3L MAPT TARDBP FMR1 SPG11 CTNS SYNJ1 TBK1 STXBP1 SYNGAP1 ATXN3 RNASEH1 SLC9A6 NOP56 TP63 VAMP1 PLAA MADD GCDH KLHL41 SNCA RRM2B PAX7 CCN2 NOTCH3 TPM3 TWNK ATP7B SIX3 SPART TP63 GLI2 GNAO1 PYROXD1 TANGO2 SOD1 SPG21 IDH1 FARS2 MSX1 TK2 ATN1 SEMA3E CDON SRPX2 LMNB1 NDUFA9 NDUFS3 GRHL3 TGIF1 FXN NUP62 SMC1A ALS2 FTL TRIP4 SPG7 OPA1 TAF1 PRDM16 POLG UBE3A MYPN PLA2G6 ZIC2 ADGRG1 GBA TK2 DISP1 COLQ FOXH1 GFPT1 NF1 XRCC1 ACTA1 UBTF KCNK9 GRIN1 CHAMP1 EIF4G1 LRRK2 FGF8 ACTA1 RERE POLG DMPK PRKCG PLXND1 MACF1 SKI B4GALNT1 TTBK2 TGIF1 HLA-DQB1 WAC SETBP1 MAPT ACTA1 NDUFAF3 ERLIN2 RRM2B TRNW SMC1A KY CDON HLA-B CHAT TDGF1 DYSF SEC31A GIGYF2 ATP1A3 PMP22 UBTF SLC25A1 PTCH1 DOCK8 PRNP MPZ ATP1A3 HOXB1 FOXH1 MYT1L GLI2 GABRD GLUD2 TUBB6 GAS1 TBP GAS1 DMPK FIG4 NF2 DYRK1A SURF1 TOP3A TGIF1 KBTBD13 CARMIL2 VCP GBA MECP2 WARS2 EBF3 POLR3A TWNK HGSNAT PI4KA GNAQ MYO9A PTCH1 COL13A1 RYR1 KLHL7 TDGF1 PRKRA TRAPPC12 PLEC FUS NDUFS2 CARS2 TGIF1 ZEB2 KIRREL3 SELENON ATXN8OS NEK1 NEFH ALS2 ATXN3 SLC52A3 HSD17B10 HPCA TDGF1 SYT14 POLG CDC73 RAB11A DLL1 FRG1 GDAP2 HLA-DRB1 SDHB HIVEP2 SHH TPM3 SIX3 GBA SNCAIP RERE CHD7 NEUROD2 ERLIN2 TCF4 MECR GRHL2 STAG2 SYT2 ATXN7 TBP ND6 MMP1 MAPT MFF CHMP1A DLL1 MED12L LRP12 SPG7 LMOD3 NODAL GRM7 ACTG2 ASAH1 SNAP25 CHRNA1 ALS2 ATP6 DLL1 PABPN1 FUS TANGO2 MID1 GRIN1 ATP6 CDH1 SDHB BMP4 CLCN1 IRF6 ACOX1 IRF5 NODAL KCNAB2 SDHC PRPH SETX SERPING1 NEU1 CHAT ABCD1 IRX5 CHCHD10 ASAH1 ITGB4 OCA2 DISP1 ATXN8OS
Protein Mutations 1
V158M
SNP 0

HPO

Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


HPO Nodes


HP:0002015: Dysphagia
Genes 639
TGIF1 ASCC1 PIGN NOS1 TRNK TIMM8A CLTC COL7A1 NODAL CACNA1G VPS35 KCNK9 CAVIN1 KAT6B PRPS1 NEB POLR3B COL7A1 SDHD SHH TUBB4A KIT PRKRA NTRK1 NGLY1 RLIM RRM2B NUTM2B-AS1 OPTN IKZF1 SPECC1L ND1 NR4A2 CAV1 CHRNE YY1 SLC5A7 MYORG STUB1 ATXN10 DNAJB6 REPS1 ATP1A3 NDUFAF2 ATXN3 DDHD2 DAB1 NEB MEGF10 NODAL ATXN8OS GUCY1A1 ACTA1 ARHGAP29 EPB41L1 DCX VARS1 PLEC FGF8 GAS1 KCNQ5 GBA NDUFA6 FOXH1 IRF6 SCN4A MSX1 ANKRD11 CHRND NEB MRPS25 LAMB2 KLHL41 TBK1 CCR6 BRSK2 CYP27A1 PNKD IRF5 QDPR TPM2 ADNP DLL1 SIX3 MYO9A TIMM8A POLG NUP62 GCH1 SATB2 DCTN1 PSEN1 GMPPA GNS FOXH1 GRIN2B ND4 ADD3 PTS CDON TAF1 CUX1 COLQ SON KLHL41 ADAR ACOX1 UBQLN2 PANK2 GAS1 CRLF1 MAPT TK2 MYOT AR NEB KMT2A SPG11 MYH8 SPECC1L TPM2 CCR6 SCN3A KDM5B ZC4H2 CDON RELN ACTA1 CHRND IRF2BPL SLC5A7 RARS1 SHH DISP1 SCN4A TRNV PUS3 KIT ZIC2 PYGM PFN1 SLC52A3 MATR3 GALC ZMYND11 DISP1 CHRNE MAP2K2 SLC25A4 KIT SHH DNAJB6 NCAPG2 FOXH1 EEF1A2 HPDL KCNC3 CDH15 LIFR TDGF1 ALS2 ADH1C VPS13A CACNG2 NGLY1 GLI2 FGF8 ATXN1 GAS1 KLHL40 ATXN8 SCN4A ECM1 ATXN2 SCO2 FGFR1 CAV1 SDHC FTL NECTIN1 ND5 KIF1A MATR3 IDH2 PUF60 PDP1 ATXN3 DNM1L UBE3A TAF1 AFG3L2 TAOK1 FBXO7 STXBP1 TDGF1 ATXN7 SLC52A2 PPP3CA ALS2 KCND3 DYNC1H1 ZIC2 UBB CAMK2A POLG DISP1 PANK2 ZEB2 STAG2 LMX1B QDPR SIX3 GJB1 SIX3 MRPS28 SLC2A3 PDGFRA PLP1 TPM3 ATXN8 EPRS1 GRIN2D FLAD1 MFF ZIC2 ASPA VAMP1 SLC44A1 NOTCH3 ADCY6 SLC25A22 ND3 POLR3A LAMA2 C9ORF72 REEP1 SACS NECTIN1 HMBS POLR3B TRPM3 FBXL4 FGF8 CYP7B1 NPC1 MED17 SHH GRM1 SYT14 CAMK2B CACNA1A DLG1 SIK1 NDUFS1 LBR CACNA1A NOP56 TBCD NODAL ATXN1 ZFYVE26 KIF5A ERLIN2 PTCH1 HTT ZIC2 SDHA SLC9A6 NPC2 PCNA SCN4A CDC73 HTT DLL1 SETX PEX16 TRAPPC12 TUBB4A SQSTM1 CIC ATP7A RNASEH1 MMP1 DEAF1 REEP1 PLAA PLA2G6 CDON CHCHD10 SLC6A9 TBC1D23 PDE8B PTCH1 TYMP POLR3A CCN2 HLA-DRB1 SNCA PTCH1 ARX TPM3 MGME1 SPG7 HLA-DQA1 C19ORF12 DGUOK STUB1 UBE3A FGF8 GLI2 SLC1A4 GLI2 AGRN BRAF SNCA CNTNAP1 POLG2 POLG ACTB VAPB APP SET SLC18A3 DLX4 SDHB TRNL1 PANK2 SPG21 FGFR1 MYH7 MYOT CHMP2B C12ORF65 RAI1 FERMT1 EXOSC9 MYMK FLCN DNAJC13 COQ2 CRYAB DKK1 LINGO1 DDHD2 LMNB1 SQSTM1 KLHL40 RHBDF2 VAMP1 CACNA1G PIK3R5 FA2H NONO ALDH18A1 MAPT WFS1 PIGA ND2 AFG3L2 DGUOK MID1 PSAP SIGMAR1 GBA2 TGM6 SCARB2 ASH1L HPRT1 TARDBP CNTNAP2 VAC14 KIAA0319L MAPT YARS2 NDUFB8 GBA MBD5 COL7A1 VAMP1 NRXN1 SLC19A3 PTS SDHC GEMIN4 COQ4 VPS13A CSNK2B RRM2B ATP13A2 PANK2 ATXN2 REV3L MAPT TARDBP FMR1 SPG11 CTNS SYNJ1 TBK1 STXBP1 SYNGAP1 ATXN3 RNASEH1 SLC9A6 NOP56 TP63 VAMP1 PLAA MADD GCDH KLHL41 SNCA RRM2B PAX7 CCN2 NOTCH3 TPM3 TWNK ATP7B SIX3 SPART TP63 GLI2 GNAO1 PYROXD1 TANGO2 SOD1 SPG21 IDH1 FARS2 MSX1 TK2 ATN1 SEMA3E CDON SRPX2 LMNB1 NDUFA9 NDUFS3 GRHL3 TGIF1 FXN NUP62 SMC1A ALS2 FTL TRIP4 SPG7 OPA1 TAF1 PRDM16 POLG UBE3A MYPN PLA2G6 ZIC2 ADGRG1 GBA TK2 DISP1 COLQ FOXH1 GFPT1 NF1 XRCC1 ACTA1 UBTF KCNK9 GRIN1 CHAMP1 EIF4G1 LRRK2 FGF8 ACTA1 RERE POLG DMPK PRKCG PLXND1 MACF1 SKI B4GALNT1 TTBK2 TGIF1 HLA-DQB1 WAC SETBP1 MAPT ACTA1 NDUFAF3 ERLIN2 RRM2B TRNW SMC1A KY CDON HLA-B CHAT TDGF1 DYSF SEC31A GIGYF2 ATP1A3 PMP22 UBTF SLC25A1 PTCH1 DOCK8 PRNP MPZ ATP1A3 HOXB1 FOXH1 MYT1L GLI2 GABRD GLUD2 TUBB6 GAS1 TBP GAS1 DMPK FIG4 NF2 DYRK1A SURF1 TOP3A TGIF1 KBTBD13 CARMIL2 VCP GBA MECP2 WARS2 EBF3 POLR3A TWNK HGSNAT PI4KA GNAQ MYO9A PTCH1 COL13A1 RYR1 KLHL7 TDGF1 PRKRA TRAPPC12 PLEC FUS NDUFS2 CARS2 TGIF1 ZEB2 KIRREL3 SELENON ATXN8OS NEK1 NEFH ALS2 ATXN3 SLC52A3 HSD17B10 HPCA TDGF1 SYT14 POLG CDC73 RAB11A DLL1 FRG1 GDAP2 HLA-DRB1 SDHB HIVEP2 SHH TPM3 SIX3 GBA SNCAIP RERE CHD7 NEUROD2 ERLIN2 TCF4 MECR GRHL2 STAG2 SYT2 ATXN7 TBP ND6 MMP1 MAPT MFF CHMP1A DLL1 MED12L LRP12 SPG7 LMOD3 NODAL GRM7 ACTG2 ASAH1 SNAP25 CHRNA1 ALS2 ATP6 DLL1 PABPN1 FUS TANGO2 MID1 GRIN1 ATP6 CDH1 SDHB BMP4 CLCN1 IRF6 ACOX1 IRF5 NODAL KCNAB2 SDHC PRPH SETX SERPING1 NEU1 CHAT ABCD1 IRX5 CHCHD10 ASAH1 ITGB4 OCA2 DISP1 ATXN8OS
Protein Mutations 1
V158M
SNP 0

Reports

Data processed on December 13, 2020.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports   MeSH Reports   HPO Reports  

Interventions

4,818 reports on interventions/drugs

MeSH

706 reports on MeSH terms

HPO

306 reports on HPO terms

All Terms

Alphabetical index of all Terms

Google Colab

Python example via Google Colab Notebook